deuruxolitinib 8 MG Oral Tablet [Leqselvi]
deuruxolitinib
RxCUI: 2716569
What the CMS Formulary Data Shows for deuruxolitinib 8 MG Oral Tablet [Leqselvi]
Per the CMS 2026 Part D formulary file, deuruxolitinib 8 MG Oral Tablet [Leqselvi] (RxNorm concept RXCUI 2716569, generic name deuruxolitinib) appears on 18 distinct formulary files spanning 150 Medicare Part D plan offerings - 3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.2.
Real-world access to deuruxolitinib 8 MG Oral Tablet [Leqselvi] depends on utilization management as much as tier placement: 94.4% of covering formularies require prior authorization. 0% require step therapy. 88.9% apply quantity limits.
Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry deuruxolitinib 8 MG Oral Tablet [Leqselvi] today.
Coverage Details
- Formularies covering
- 18
- Plans covering
- 150
- Coverage rate
- 3%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 94.4% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 88.9% of formularies
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering deuruxolitinib 8 MG Oral Tablet [Leqselvi]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is deuruxolitinib 8 MG Oral Tablet [Leqselvi] covered by Medicare Part D?
Yes, deuruxolitinib 8 MG Oral Tablet [Leqselvi] is covered by 150 Medicare Part D plans (3% of all Part D formularies).
What tier is deuruxolitinib 8 MG Oral Tablet [Leqselvi] on Medicare Part D plans?
deuruxolitinib 8 MG Oral Tablet [Leqselvi] averages Tier 4.2 across Part D plans, ranging from Tier 1 to Tier 5.
Does deuruxolitinib 8 MG Oral Tablet [Leqselvi] require prior authorization?
94.4% of Part D formularies require prior authorization for deuruxolitinib 8 MG Oral Tablet [Leqselvi]. Step therapy: 0%. Quantity limits: 88.9%.
Read our methodology - how this data is sourced, computed, and verified.